Combination of dual-targeted therapies and chemotherapy shows high response
rates in BRAF-mutated metastatic colorectal cancer
-
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E
mutations benefited from first-line treatment with the targeted therapies
encorafeni...
9 hours ago
0 comments:
Post a Comment